Summary
Global Markets Direct’s, ‘Kadmon Corporation, LLC - Product Pipeline Review - 2016’, provides an overview of the Kadmon Corporation, LLC’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Kadmon Corporation, LLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Kadmon Corporation, LLC
- The report provides overview of Kadmon Corporation, LLC including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Kadmon Corporation, LLC’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Kadmon Corporation, LLC’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Kadmon Corporation, LLC’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kadmon Corporation, LLC
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kadmon Corporation, LLC’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Kadmon Corporation, LLC Snapshot 5
Kadmon Corporation, LLC Overview 5
Key Information 5
Key Facts 5
Kadmon Corporation, LLC - Research and Development Overview 6
Key Therapeutic Areas 6
Kadmon Corporation, LLC - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Kadmon Corporation, LLC - Pipeline Products Glance 13
Kadmon Corporation, LLC - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Kadmon Corporation, LLC - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Kadmon Corporation, LLC - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Kadmon Corporation, LLC - Drug Profiles 18
trientine hydrochloride next generation 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
KD-025 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
KD-026 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
tesevatinib tosylate 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Gene Therapy to Activate Aquaporin-1 for Xerostomia 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
salirasib 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
KD-033 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
KL-00148 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
KL-00199 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibodies to Inhibit PDL1 for Oncology 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Monoclonal Antibody to Inhibit VEGFR-2 for Cancer 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Kadmon Corporation, LLC - Pipeline Analysis 34
Kadmon Corporation, LLC - Pipeline Products by Target 34
Kadmon Corporation, LLC - Pipeline Products by Route of Administration 36
Kadmon Corporation, LLC - Pipeline Products by Molecule Type 37
Kadmon Corporation, LLC - Pipeline Products by Mechanism of Action 38
Kadmon Corporation, LLC - Recent Pipeline Updates 39
Kadmon Corporation, LLC - Dormant Projects 44
Kadmon Corporation, LLC - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47
List of Tables
Kadmon Corporation, LLC, Key Information 5
Kadmon Corporation, LLC, Key Facts 5
Kadmon Corporation, LLC - Pipeline by Indication, 2016 7
Kadmon Corporation, LLC - Pipeline by Stage of Development, 2016 9
Kadmon Corporation, LLC - Monotherapy Products in Pipeline, 2016 10
Kadmon Corporation, LLC - Partnered Products in Pipeline, 2016 11
Kadmon Corporation, LLC - Partnered Products/ Combination Treatment Modalities, 2016 12
Kadmon Corporation, LLC - Phase III, 2016 13
Kadmon Corporation, LLC - Phase II, 2016 14
Kadmon Corporation, LLC - Phase I, 2016 15
Kadmon Corporation, LLC - Preclinical, 2016 16
Kadmon Corporation, LLC - Discovery, 2016 17
Kadmon Corporation, LLC - Pipeline by Target, 2016 34
Kadmon Corporation, LLC - Pipeline by Route of Administration, 2016 36
Kadmon Corporation, LLC - Pipeline by Molecule Type, 2016 37
Kadmon Corporation, LLC - Pipeline Products by Mechanism of Action, 2016 38
Kadmon Corporation, LLC - Recent Pipeline Updates, 2016 39
Kadmon Corporation, LLC - Dormant Developmental Projects,2016 44
Kadmon Corporation, LLC, Other Locations 45
Kadmon Corporation, LLC, Subsidiaries 45
List of Figures
Kadmon Corporation, LLC - Pipeline by Top 10 Indication, 2016 7
Kadmon Corporation, LLC - Pipeline by Stage of Development, 2016 9
Kadmon Corporation, LLC - Monotherapy Products in Pipeline, 2016 10
Kadmon Corporation, LLC - Pipeline by Top 10 Target, 2016 34
Kadmon Corporation, LLC - Pipeline by Route of Administration, 2016 36
Kadmon Corporation, LLC - Pipeline by Molecule Type, 2016 37
Kadmon Corporation, LLC - Pipeline Products by Top 10 Mechanism of Action, 2016 38
